Literature DB >> 7963706

Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.

M L Tsang1, L A Evans, P McQueen, L Hurren, C Byrne, R Penny, B Tindall, D A Cooper.   

Abstract

The emergence of human immunodeficiency virus type 1 (HIV-1) variants with different sensitivities to serum neutralization and biologic phenotype was studied for 2-5 years after primary HIV-1 infection in 5 subjects. In 3 subjects, the initial virus isolate from seroconversion could be neutralized by autologous serum, but isolates obtained at two subsequent times exhibited reduced sensitivity to serum neutralization, decreased replication in primary macrophages, and increased ability to induce syncytia. Two of these 3 subjects progressed to AIDS and died. Sequential virus isolates from the other 2 subjects showed variability in sensitivity to serum neutralization or biologic features. These patients remained relatively stable in clinical status. Thus, viruses isolated at seroconversion appear to be either non-syncytium-inducing, strong macrophage-tropic, serum neutralization-sensitive phenotypes with stable clinical status or to have escaped neutralization by autologous sera over time, have reduced macrophage tropism and increased syncytia formation, and be associated with disease progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963706     DOI: 10.1093/infdis/170.5.1141

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.

Authors:  L Sarmati; G d'Ettorre; E Nicastri; L Ercoli; I Uccella; P Massetti; S G Parisi; V Vullo; M Andreoni
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.

Authors:  D Del Mauro; D Matteucci; S Giannecchini; F Maggi; M Pistello; M Bendinelli
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

7.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Biol Sci       Date:  1998-11-22       Impact factor: 5.349

9.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Authors:  Phillipe Nyambi; Sherri Burda; Mateusz Urbanski; Leo Heyndrickx; Wouter Janssens; Guido Vanham; Arthur Nadas
Journal:  AIDS Res Hum Retroviruses       Date:  2008-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.